News
Media
Conferences
CME/CE
Partners
Publications
Resources
Subscribe

Global Approaches to the Management of Relapsing Multiple Sclerosis

EP. 1: Diagnosis of Multiple Sclerosis: The McDonald Criteria

BySven Meuth, MD, PhD,Patricia Coyle, MD,Wallace Brownlee, MBChB, PhD, FRACP,Fred D. Lublin, MD

September 3rd 2020

EP. 2: Differential Diagnosis of Multiple Sclerosis

BySven Meuth, MD, PhD,Patricia Coyle, MD,Wallace Brownlee, MBChB, PhD, FRACP,Fred D. Lublin, MD

September 3rd 2020

EP. 3: MOG-IgG in Multiple Sclerosis

BySven Meuth, MD, PhD,Patricia Coyle, MD,Wallace Brownlee, MBChB, PhD, FRACP,Fred D. Lublin, MD

September 3rd 2020

EP. 4: Clinically Isolated Syndrome Versus Multiple Sclerosis

BySven Meuth, MD, PhD,Patricia Coyle, MD,Wallace Brownlee, MBChB, PhD, FRACP,Fred D. Lublin, MD

September 3rd 2020

EP. 5: First-Line Therapies for Relapsing Multiple Sclerosis

BySven Meuth, MD, PhD,Patricia Coyle, MD,Wallace Brownlee, MBChB, PhD, FRACP,Fred D. Lublin, MD

September 3rd 2020

EP. 6: The Use of Interferon in Multiple Sclerosis

BySven Meuth, MD, PhD,Patricia Coyle, MD,Wallace Brownlee, MBChB, PhD, FRACP,Fred D. Lublin, MD

September 3rd 2020

EP. 7: The Use of Glatiramer Acetate in Multiple Sclerosis

BySven Meuth, MD, PhD,Patricia Coyle, MD,Wallace Brownlee, MBChB, PhD, FRACP,Fred D. Lublin, MD

September 3rd 2020

EP. 8: Clinical Trials for Cladribine in Multiple Sclerosis

BySven Meuth, MD, PhD,Patricia Coyle, MD,Wallace Brownlee, MBChB, PhD, FRACP,Fred D. Lublin, MD

September 3rd 2020

EP. 9: Treating With Cladribine in Multiple Sclerosis

BySven Meuth, MD, PhD,Patricia Coyle, MD,Wallace Brownlee, MBChB, PhD, FRACP,Fred D. Lublin, MD

September 3rd 2020

EP. 10: Role of Siponimod in Multiple Sclerosis

BySven Meuth, MD, PhD,Patricia Coyle, MD,Wallace Brownlee, MBChB, PhD, FRACP,Fred D. Lublin, MD

September 3rd 2020

EP. 11: Ocrelizumab for the Treatment of Multiple Sclerosis

BySven Meuth, MD, PhD,Patricia Coyle, MD,Wallace Brownlee, MBChB, PhD, FRACP,Fred D. Lublin, MD

September 3rd 2020

EP. 12: Role of Ocrelizumab in Europe for Multiple Sclerosis

BySven Meuth, MD, PhD,Patricia Coyle, MD,Wallace Brownlee, MBChB, PhD, FRACP,Fred D. Lublin, MD

September 3rd 2020

EP. 13: Role of Diroximel Fumarate in Multiple Sclerosis

BySven Meuth, MD, PhD,Patricia Coyle, MD,Wallace Brownlee, MBChB, PhD, FRACP,Fred D. Lublin, MD

September 3rd 2020

EP. 14: Role of Ozanimod in Multiple Sclerosis

BySven Meuth, MD, PhD,Patricia Coyle, MD,Wallace Brownlee, MBChB, PhD, FRACP,Fred D. Lublin, MD

September 3rd 2020

EP. 15: Switching Therapies in Multiple Sclerosis

BySven Meuth, MD, PhD,Patricia Coyle, MD,Wallace Brownlee, MBChB, PhD, FRACP,Fred D. Lublin, MD

September 3rd 2020

EP. 16: Decision-Making Process for Treating Multiple Sclerosis

BySven Meuth, MD, PhD,Patricia Coyle, MD,Wallace Brownlee, MBChB, PhD, FRACP,Fred D. Lublin, MD

September 3rd 2020

EP. 17: The Future of Treating Multiple Sclerosis

BySven Meuth, MD, PhD,Patricia Coyle, MD,Wallace Brownlee, MBChB, PhD, FRACP,Fred D. Lublin, MD

September 3rd 2020

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

Insights on Vibrance-2 Study Results of Alixorexton in Narcolepsy Type 2: Richard K. Bogan, MD, FCCP, FAASM

FDA Clears Investigational New Drug Application for Remyelinating Agent PTD802 in Multiple Sclerosis

Pipeline Review: Alzheimer Disease Therapies by Mechanism of Action

New Deep Learning Tool Forecasts Alzheimer Disease Progression From Baseline MRI

FDA and EMA Accepts Regulatory Applications for Cemdisiran in Generalized Myasthenia Gravis